S&P 500   3,699.12 (+0.88%)
DOW   30,218.26 (+0.83%)
QQQ   305.52 (+0.41%)
AAPL   122.25 (-0.56%)
MSFT   214.36 (+0.06%)
FB   279.70 (-0.76%)
GOOGL   1,823.76 (+0.11%)
AMZN   3,162.58 (-0.76%)
TSLA   599.04 (+0.95%)
NVDA   542.33 (+1.21%)
BABA   267.25 (+0.13%)
CGC   28.59 (-0.14%)
GE   10.88 (+2.64%)
MU   73.34 (+4.92%)
AMD   94.04 (+1.87%)
T   29.54 (+1.06%)
NIO   43.04 (-5.09%)
F   9.34 (+1.41%)
ACB   10.89 (-3.11%)
BA   232.71 (-1.89%)
NFLX   498.31 (+0.16%)
GILD   61.56 (+1.15%)
DIS   154.14 (+0.59%)
S&P 500   3,699.12 (+0.88%)
DOW   30,218.26 (+0.83%)
QQQ   305.52 (+0.41%)
AAPL   122.25 (-0.56%)
MSFT   214.36 (+0.06%)
FB   279.70 (-0.76%)
GOOGL   1,823.76 (+0.11%)
AMZN   3,162.58 (-0.76%)
TSLA   599.04 (+0.95%)
NVDA   542.33 (+1.21%)
BABA   267.25 (+0.13%)
CGC   28.59 (-0.14%)
GE   10.88 (+2.64%)
MU   73.34 (+4.92%)
AMD   94.04 (+1.87%)
T   29.54 (+1.06%)
NIO   43.04 (-5.09%)
F   9.34 (+1.41%)
ACB   10.89 (-3.11%)
BA   232.71 (-1.89%)
NFLX   498.31 (+0.16%)
GILD   61.56 (+1.15%)
DIS   154.14 (+0.59%)
S&P 500   3,699.12 (+0.88%)
DOW   30,218.26 (+0.83%)
QQQ   305.52 (+0.41%)
AAPL   122.25 (-0.56%)
MSFT   214.36 (+0.06%)
FB   279.70 (-0.76%)
GOOGL   1,823.76 (+0.11%)
AMZN   3,162.58 (-0.76%)
TSLA   599.04 (+0.95%)
NVDA   542.33 (+1.21%)
BABA   267.25 (+0.13%)
CGC   28.59 (-0.14%)
GE   10.88 (+2.64%)
MU   73.34 (+4.92%)
AMD   94.04 (+1.87%)
T   29.54 (+1.06%)
NIO   43.04 (-5.09%)
F   9.34 (+1.41%)
ACB   10.89 (-3.11%)
BA   232.71 (-1.89%)
NFLX   498.31 (+0.16%)
GILD   61.56 (+1.15%)
DIS   154.14 (+0.59%)
S&P 500   3,699.12 (+0.88%)
DOW   30,218.26 (+0.83%)
QQQ   305.52 (+0.41%)
AAPL   122.25 (-0.56%)
MSFT   214.36 (+0.06%)
FB   279.70 (-0.76%)
GOOGL   1,823.76 (+0.11%)
AMZN   3,162.58 (-0.76%)
TSLA   599.04 (+0.95%)
NVDA   542.33 (+1.21%)
BABA   267.25 (+0.13%)
CGC   28.59 (-0.14%)
GE   10.88 (+2.64%)
MU   73.34 (+4.92%)
AMD   94.04 (+1.87%)
T   29.54 (+1.06%)
NIO   43.04 (-5.09%)
F   9.34 (+1.41%)
ACB   10.89 (-3.11%)
BA   232.71 (-1.89%)
NFLX   498.31 (+0.16%)
GILD   61.56 (+1.15%)
DIS   154.14 (+0.59%)
Log in
NASDAQ:YMAB

Y-mAbs Therapeutics Stock Forecast, Price & News

$51.29
+0.59 (+1.16 %)
(As of 12/4/2020 04:30 PM ET)
Add
Compare
Today's Range
$49.20
Now: $51.29
$51.65
50-Day Range
$37.86
MA: $44.48
$52.16
52-Week Range
$14.16
Now: $51.29
$55.22
Volume147,077 shs
Average Volume208,119 shs
Market Capitalization$2.08 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.36
Y-mAbs Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment cancer in the United States. The company develops naxitamab that is in Phase 2 clinical trial for the treatment of pediatric patients with relapsed steosarcoma or refractory, and high-risk neuroblastoma, as well as other GD2 positive tumors; and GD2-GD3 Vaccine which is in Phase 2 clinical trial for the treatment of high-risk neuroblastoma. It is developing omburtamab that is in Phase 2 clinical trial for the treatment of desmoplastic small round cell tumors; in Phase 1 clinical trial for the treatment of diffuse intrinsic pontine glioma, as well as for the treatment of pediatric patients with central nervous system and leptomeningeal metastases; The company also engages in the development of huB7-H3 product candidate for the treatment of B7-H3 positive adult solid tumors; and pre clinical development of huCD33 BsAb product candidate for the treatment of huCD33 positive hermatological cancers. The company has a license and research collaboration agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize antibody constructs based on the SADA-BiDE pre-targeted radioimmunotherapy platform. Y-mAbs Therapeutics, Inc. was founded in 2015 and is headquartered in New York, New York.
Y-mAbs Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.4Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.23 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:YMAB
CUSIPN/A
CIKN/A
Phone646-885-8505
Employees65

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$5.01 per share

Profitability

Net Income$-81,030,000.00

Miscellaneous

Market Cap$2.08 billion
Next Earnings Date3/11/2021 (Estimated)
OptionableNot Optionable
$51.29
+0.59 (+1.16 %)
(As of 12/4/2020 04:30 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive YMAB News and Ratings via Email

Sign-up to receive the latest news and ratings for YMAB and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Y-mAbs Therapeutics (NASDAQ:YMAB) Frequently Asked Questions

How has Y-mAbs Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

Y-mAbs Therapeutics' stock was trading at $22.98 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, YMAB stock has increased by 120.3% and is now trading at $50.62.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Y-mAbs Therapeutics?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Y-mAbs Therapeutics in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Y-mAbs Therapeutics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Y-mAbs Therapeutics?

Wall Street analysts have given Y-mAbs Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Y-mAbs Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Y-mAbs Therapeutics' next earnings date?

Y-mAbs Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 11th 2021.
View our earnings forecast for Y-mAbs Therapeutics
.

How were Y-mAbs Therapeutics' earnings last quarter?

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) posted its quarterly earnings results on Thursday, November, 12th. The company reported ($0.82) earnings per share for the quarter, missing the consensus estimate of ($0.80) by $0.02.
View Y-mAbs Therapeutics' earnings history
.

What price target have analysts set for YMAB?

8 brokers have issued twelve-month target prices for Y-mAbs Therapeutics' stock. Their forecasts range from $39.00 to $65.00. On average, they anticipate Y-mAbs Therapeutics' stock price to reach $49.67 in the next twelve months. This suggests that the stock has a possible downside of 1.9%.
View analysts' price targets for Y-mAbs Therapeutics
.

Who are some of Y-mAbs Therapeutics' key competitors?

What other stocks do shareholders of Y-mAbs Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Y-mAbs Therapeutics investors own include Bank of Hawaii (BOH), InterDigital (IDCC), STAG Industrial (STAG), Corbus Pharmaceuticals (CRBP), CTI BioPharma (CTIC), Nabriva Therapeutics (NBRV), Occidental Petroleum (OXY), VBI Vaccines (VBIV), Vaxart (VXRT) and Amarin (AMRN).

Who are Y-mAbs Therapeutics' key executives?

Y-mAbs Therapeutics' management team includes the following people:
  • Mr. Thomas Gad, Founder, Chairman, Pres & Head of Bus. Devel. and Strategy (Age 50, Pay $766.75k)
  • Dr. Claus Juan Møller San Pedro M.D., Ph.D., CEO & Director (Age 58, Pay $967.5k)
  • Mr. Bo Kruse, Exec. VP, Sec., Treasurer & CFO (Age 48, Pay $608.35k)
  • Mr. Joris Wiel Jan Wilms, Sr. VP & COO (Age 46)
  • Dr. Torben Lund-Hansen, Sr. VP & Head of Technical Operations (Age 69)
  • Dr. Steen Lisby M.D., M.Sc., Sr. VP & Chief Scientific Officer (Age 56)
  • Mr. Philip Herman, Sr. VP & Chief Commercial Officer (Age 41)
  • Dr. Vignesh Rajah, Sr. VP & Chief Medical Officer

When did Y-mAbs Therapeutics IPO?

(YMAB) raised $80 million in an initial public offering (IPO) on Friday, September 21st 2018. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Canaccord Genuity served as the underwriters for the IPO and BTIG was co-manager.

What is Y-mAbs Therapeutics' stock symbol?

Y-mAbs Therapeutics trades on the NASDAQ under the ticker symbol "YMAB."

Who are Y-mAbs Therapeutics' major shareholders?

Y-mAbs Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.86%), State Street Corp (2.62%), First Light Asset Management LLC (1.50%), Great West Life Assurance Co. Can (1.00%), Sphera Funds Management LTD. (0.98%) and AXA S.A. (0.47%). Company insiders that own Y-mAbs Therapeutics stock include Bo Kruse, David N Gill, James Healy, Johan Wedell-Wedellsborg, Mahiuddin Ahmed, Pedro Claus Juan Moller-San and Thomas Gad.
View institutional ownership trends for Y-mAbs Therapeutics
.

Which institutional investors are selling Y-mAbs Therapeutics stock?

YMAB stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Alps Advisors Inc., Alps Advisors Inc., Wells Fargo & Company MN, AXA S.A., JPMorgan Chase & Co., Virtus ETF Advisers LLC, and Squarepoint Ops LLC. Company insiders that have sold Y-mAbs Therapeutics company stock in the last year include Bo Kruse, David N Gill, Mahiuddin Ahmed, Pedro Claus Juan Moller-San, and Thomas Gad.
View insider buying and selling activity for Y-mAbs Therapeutics
.

Which institutional investors are buying Y-mAbs Therapeutics stock?

YMAB stock was bought by a variety of institutional investors in the last quarter, including Great West Life Assurance Co. Can, Sphera Funds Management LTD., State Street Corp, SG Americas Securities LLC, BlackRock Inc., Charles Schwab Investment Management Inc., New York State Common Retirement Fund, and Federated Hermes Inc.. Company insiders that have bought Y-mAbs Therapeutics stock in the last two years include James Healy, and Pedro Claus Juan Moller-San.
View insider buying and selling activity for Y-mAbs Therapeutics
.

How do I buy shares of Y-mAbs Therapeutics?

Shares of YMAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Y-mAbs Therapeutics' stock price today?

One share of YMAB stock can currently be purchased for approximately $50.62.

How big of a company is Y-mAbs Therapeutics?

Y-mAbs Therapeutics has a market capitalization of $2.05 billion. The company earns $-81,030,000.00 in net income (profit) each year or ($2.30) on an earnings per share basis. Y-mAbs Therapeutics employs 65 workers across the globe.

What is Y-mAbs Therapeutics' official website?

The official website for Y-mAbs Therapeutics is www.ymabs.com.

How can I contact Y-mAbs Therapeutics?

Y-mAbs Therapeutics' mailing address is 230 Park Avenue Suite 3350, NEW YORK NY, 10169. The company can be reached via phone at 646-885-8505 or via email at [email protected]

This page was last updated on 12/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.